# RxREVU

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rxrevu

- Industry: Healthcare IT
- Headquarters: Denver, US
- Website: www.rxrevu.com
- Total disclosed funding: $23M
- Latest round: Series B (Jan 27, 2021)
- Investors on record: 7

## About

Based in Colorado, US, and founded in 2013 by Carm Huntress, Dan Caron, Kevin O'Brien, Peregrin Marshall, and Scott Ward, RxREVU, Inc., trading under the name Arrive Health, operates as a Prescription Decision Support company that develops a prescription intelligence platform designed to manage and measure doctor's prescribing performance. The company has reached 2,000 hospitals in less than two years. A series B funding was recently received and was led by returning investor Jazz Venture Partners. In March 2026, Arrive Health merged with DoseSpot to form Interra Health.

The company's technology includes SwiftRx Direct, which brings real-time, patient and pharmacy-specific cost information, coverage restrictions, and therapeutic alternatives into native electronic health record (EHR) workflows; SwiftRx Navigator, which combines evidence-based guidelines, therapeutic alternatives, and real-time, patient-specific cost information in an EHR-embedded decision support application; and SwiftRx Insights, which provides behavioral analytics to help organizations reduce care variability, improve patient safety, and manage pharmacy risk. RxREVU delivers custom reporting to analyze actionable insights and tracks the critical metrics around prescribing drugs to patients based on their medical history, drug allergies, and insurance coverage, enabling healthcare professionals to make more informed prescribing decisions.

RxRevu partners with providers, payers, and pharmacy benefit managers, and EHR vendors to improve healthcare by providing accurate, patient-specific coverage and cost data at the point-of-care. Its technology solution will help physicians quickly and easily find affordable care options specific to a patient's health and financial needs.

The company's recent funding will fuel the development of SwiftRx, facilitate growth in personnel and technical capabilities.

## Funding rounds

- Series B, Jan 27, 2021, $7M — JAZZ Venture Partners
- Series A, May 31, 2019, $16M — JAZZ Venture Partners, UVA Licensing & Ventures Group, UCHealth, Froedtert Health, UnityPoint Health Ventures, Presbyterian Healthcare Services, Children’s Hospital Colorado

## Investors

- JAZZ Venture Partners (https://capitalatlas.ai/funds/jazz-venture-partners) — Series A, Series B
- UVA Licensing & Ventures Group (https://capitalatlas.ai/funds/uva-licensing-ventures-group) — Series A
- UCHealth — Series A
- Froedtert Health — Series A
- UnityPoint Health Ventures (https://capitalatlas.ai/funds/unitypoint-health-ventures) — Series A
- Presbyterian Healthcare Services — Series A
- Children’s Hospital Colorado — Series A